Expanded Access Treatment of Zidesamtinib (NVL-520) in Patients with Advanced ROS1+ NSCLC
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Zidesamtinib (Primary)
- Indications Non-small cell lung cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Nuvalent
- 03 Feb 2025 New trial record